Process Validation: Using Tolerance Intervals for Setting Process Validation Acceptance Criteria - - BioPharm International

ADVERTISEMENT

Process Validation: Using Tolerance Intervals for Setting Process Validation Acceptance Criteria


BioPharm International
Volume 20, Issue 6

ABSTRACT

One goal of process characterization is establishing representative performance parameter ranges that can be used to set validation acceptance criteria (VAC). Characterization studies yield varying numbers of data points from multiple experiments, and may also include data generated at different scales (e.g., bench, pilot, and commercial), which add complexity to the analysis. Many statistical approaches can be used to set ranges from large data sets. As an example, we present the statistical considerations and techniques for setting validation acceptance ranges for a chromatography step used in purifying a recombinant protein. Performance parameter data from a combined data set consisting of 67 bench, six pilot, and three full-scale runs were analyzed using the statistical analysis software JMP (SAS Institute). The combined data set was used to compute tolerance intervals, so that sources such as scale and column feed material could be properly modeled. The resulting ranges were used to establish validation acceptance criteria.



Process validation provides the documented evidence that a given process, operated within established parameters, can effectively and reproducibly produce an intermediate, active pharmaceutical ingredient (API), or drug product meeting predetermined criteria and quality attributes. While final drug products and APIs must meet specifications based on standards mandated by safety concerns and other factors, intermediate process steps do not have such mandated standards. However, they still must meet a number of acceptance criteria to demonstrate process consistency and other required product quality attributes to meet final specifications.

Establishing appropriate validation acceptance criteria (VAC) is one of the greatest challenges in the development of a commercial biopharmaceutical manufacturing process. Setting VAC that are too broad will not enable demonstration of adequate process control. VAC that are too narrow can result in failed validation runs, even though the process may be performing adequately.

If there are no representative bench-scale data from process characterization studies, the data set used for a statistical analysis to establish acceptance criteria may be quite small. Yet, if both process characterization data from bench scale studies, as well as data from large-scale runs are available, it may not be obvious how to combine these data sets in an appropriate way. In this article, we describe statistical methods in which bench-scale process characterization data are combined with a smaller, large-scale data set to establish validation acceptance criteria that are indicative of process consistency, yet are not unduly restrictive.

PROCESS CHARACTERIZATION


Table 1. Process characterization definitions.
Process characterization involves bench-scale studies performed to demonstrate process robustness and to help predict the performance of the process within the constraints of the operational ranges that will be used in manufacturing. One approach to process characterization has been described previously.1 Briefly, operating parameters (OPs) that are most likely to impact the process performance parameters (PPs) are identified by a risk analysis (e.g., failure modes and effects analysis2,3 ). These parameters are then tested outside their normal operating range (OR) (typically 2–3X outside the OR) to determine process robustness (ROB) and to eliminate from further study any OPs that have no effect on the process over this range. Those parameters exhibiting significant effects in the robustness study are tested to the edge of their OR (EOR) in a second study designed to identify two-way statistical interactions between OPs. From these studies, we can predict the expected performance of the process within the constraints of all ORs. Table 1 provides definitions for process characterization.

TOLERANCE INTERVALS AS PROCESS VALIDATION CRITERIA

A two-sided tolerance interval is an interval thought to contain 100p% of a population with 100(1 – α)% confidence. For example, if p = 0.99 and α = 0.05, then a two-sided tolerance interval will contain 99% of the population with 95% confidence. This means that the reported range is expected to include 99% of the PP values that will be generated by the process under consideration. Tolerance intervals are particularly useful for setting VAC because they describe the expected long-range behavior of the process.

Tolerance intervals can be computed and used to set VAC under any of the following scenarios:

  • When only data from large-scale runs are available, and there are no bench-scale data that adequately represent the full-scale process. (Typically, this may be a relatively small data set.)
  • When bench data derived from process characterization experimental design studies are combined with large-scale runs to compute tolerance intervals at

a. setpoint conditions; or as
b. OPs move within the OR.

Examples of calculating tolerance intervals computed for each of these scenarios appear in the three scenarios that follow.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here